NIVOLUMAB WITH AZACYTIDINE IN PEDIATRIC RELAPSED/REFRACTORY AML:PHASE I RESULTS FROM TACL CONSORTIUM

被引：0
|
作者：
Verma, Anupam [1 ]
Chi, Yueh-Yun [1 ]
Malvar, Jemily [1 ]
Lamble, Adam [1 ]
Chaudhury, Sonali [1 ]
Sung, Lillian [1 ]
Agarwal, Archana [1 ]
Liang, Gangning [1 ]
Sposto, Richard [1 ]
Leong, Roy [1 ]
Brown, Patrick [1 ]
Kaplan, Joel [1 ]
Schafer, Eric [1 ]
Slone, Tamra [1 ]
Pauly, Melinda [1 ]
Chang, Bill [1 ]
Stieglitz, Elliot [1 ]
Wayne, Alan [1 ]
Hijiya, Nobuko [1 ]
Bhoywani, Deepa [1 ]
机构：
[1] Therapeut Adv Childhood Leukemia & Lymphoma, Salt Lake City, UT USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
    Jonathan L. Kaufman
    Roberto Mina
    Andrzej J. Jakubowiak
    Todd L. Zimmerman
    Jeffrey J. Wolf
    Colleen Lewis
    Charise Gleason
    Cathy Sharp
    Thomas Martin
    Leonard T. Heffner
    Ajay K. Nooka
    R. Donald Harvey
    Sagar Lonial
    Blood Cancer Journal, 9
  • [32] Results From a Phase 1/2 Study of Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 13
  • [33] Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Herrera, Alex F.
    Moskowitz, Alison J.
    Bartlett, Nancy L.
    Vose, Julie M.
    Ramchandren, Radhakrishnan
    Feldman, Tatyana A.
    LaCasce, Ann S.
    Ansell, Stephen M.
    Moskowitz, Craig H.
    Fenton, Keenan
    Ogden, Carol Anne
    Taft, David
    Zhang, Qu
    Kato, Kazunobu
    Campbell, Mary
    Advani, Ranjana H.
    BLOOD, 2017, 130
  • [34] A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study
    Hummel, T. R.
    Wagner, L. M.
    Ahern, C. H.
    McGovern, R. M.
    Ames, M. M.
    Gilbertson, R. J.
    Horton, T. M.
    Ingle, A. M.
    Weigel, B.
    Blaney, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Phase I trial and pharmacokinetics (PK) of lenalidomide in pediatric patients with relapsed/refractory solid tumors or MDS: A Children's Oncology Group phase I consortium study
    Russell, H.
    Cairo, M. S.
    Blaney, S. M.
    Adamson, P. C.
    Ingle, A. M.
    Berg, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies
    Geoerger, Birgit
    Doz, Francois
    Gentet, Jean-Claude
    Mayer, Michele
    Landman-Parker, Judith
    Pichon, Fabienne
    Chastagner, Pascal
    Rubie, Herve
    Frappaz, Didier
    Le Bouil, Anne
    Gupta, Sunil
    Vassal, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4394 - 4400
  • [37] Prognostic Significance of Time to Relapse in Pediatric AML: Results from the International Randomised Phase III Study Relapsed AML 2001/01
    Kaspers, G. J. L.
    Zimmermann, M.
    Reinhardt, D.
    Gibson, B.
    Tamminga, R.
    Armendariz, H.
    Dworzak, M.
    Ha, S.
    Hovi, L.
    Maschan, A.
    Baruchel, A.
    Bertrand, Y.
    Razzouk, B.
    Rizzari, C.
    Smisek, P.
    Smith, O.
    Stark, B.
    Creutzig, U.
    BLOOD, 2008, 112 (11) : 1022 - 1023
  • [38] A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study
    Cooper, Todd Michael
    Malvar, Jemily
    Cassar, Jeannette
    Eckroth, Elena
    Sposto, Richard
    Gaynon, Paul
    Dubois, Steven
    Gore, Lia
    Macy, Margaret E.
    August, Keith J.
    Thomson, Blythe
    Oesterheld, Javier
    Gammon, Guy
    Magoon, Daniel
    Annesley, Colleen E.
    Brown, Patrick
    BLOOD, 2013, 122 (21)
  • [39] Dasatinib(SPRVCEL®) in children and adolescents with relapsed or refractory leukemia:: Preliminary results of the CA180018 phase I/II study from the ITCC consortium
    Zwaan, Christian M.
    Den Boer, M. L.
    Beverloo, H. B.
    Velden, V. H. J. Van. Der
    VanTornout, J. M. A.
    Derreumaux, D.
    Baruchel, A.
    Rizzari, C.
    Kearns, P.
    Pieters, R.
    BLOOD, 2007, 110 (11) : 318A - 318A
  • [40] Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
    Phillips, Tycel Jovelle
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Crump, Michael
    Trneny, Marek
    Bartlett, Nancy L.
    Zaucha, Jan
    Wrobel, Tomasz
    Offner, Fritz
    Humphrey, Kathryn
    Relf, James
    de L'Etang, Audrey Filezac
    Carlile, David J.
    Byrne, Ben
    Qayum, Naseer
    Lundberg, Linda
    Dickinson, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
12345